Anzeige
Mehr »
Login
Freitag, 08.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus" in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XDTV | ISIN: NL0010696654 | Ticker-Symbol: UQ1
Tradegate
07.11.24
18:52 Uhr
6,902 Euro
+0,020
+0,29 %
1-Jahres-Chart
UNIQURE NV Chart 1 Jahr
5-Tage-Chart
UNIQURE NV 5-Tage-Chart
RealtimeGeldBriefZeit
6,7566,92612:51
6,7566,92612:21

Aktuelle News zur UNIQURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiuniQure N.V. - 10-Q, Quarterly Report1
DiuniQure GAAP EPS of -$0.91 beats by $0.03, revenue of $2.29M misses by $4.77M2
DiuniQure Inc.: uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress167~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington's disease ~ ~...
► Artikel lesen
DiuniQure N.V. - 8-K, Current Report-
15.10.uniQure N.V. - 8-K, Current Report7
15.10.uniQure Inc.: uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS311LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first...
► Artikel lesen
10.10.uniQure shares coverage resumed on robust clinical portfolio15
23.09.uniQure N.V. - 8-K, Current Report4
23.09.FDA grants Orphan Drug status to uniQure's Fabry therapy6
23.09.uniQure Inc.: uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease281LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the...
► Artikel lesen
20.08.uniQure retains PT with Buy rating on gene therapy prospects15
15.08.uniQure N.V. - 8-K, Current Report1
15.08.uniQure Inc.: uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease437LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first...
► Artikel lesen
05.08.uniQure wields axe again as Huntington's therapy progresses5
02.08.UniQure to cut 65% of workforce, or 300 jobs, in major restructuring3
01.08.UniQure restructuring to claim 300 jobs4
01.08.UniQure, Arbutus and HilleVax all lay off staff as biotechs streamline operations and cut costs4
01.08.uniQure N.V. - S-8, Securities to be offered to employees in employee benefit plans3
01.08.uniQure N.V. - 8-K, Current Report1
01.08.uniQure N.V. - 10-Q, Quarterly Report2
Seite:  Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1